

FIRST TIME GENERIC APPROVAL

Brand Name	Jadenu® Sprinkle
Generic Name	deferasirox
Drug Manufacturer	Alkem Laboratories Ltd.

New Drug Approval

Dosage form(s): 90 mg, 180 mg and 360 mg Oral Granules
Therapeutic equivalent code: AB
FDA Approval Date: July 14, 2020

Indications for Use

deferasirox is indicated for:

- To treat iron overload caused by blood transfusions in adults and children at least 2 years old.
- To treat chronic iron overload syndrome caused by a genetic blood disorder in adults and children who are at least 10 years old.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.